Healthy Skepticism Library item: 9887
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Brocvielle H, Muret P, Plenat E, Kantelip JP, Humbert P.
Management of a patient receiving thalidomide
Presse Med. 2003 Dec 20; 32:(40):1894-8
http://www.masson.fr/masson/portal/bookmark?Global=1&Page=18&MenuIdSelected=106&MenuItemSelected=0&MenuSupportSelected=0&CodeProduct4=100&CodeRevue4=PM&Path=REVUE/PM/2003/32/40/ARTICLE1110875240.xml&Locations=
Abstract:
The use of a drug with a temporary marketing autorisation Thalidomaide is currently available in France for nominative or cohort use with a temporary marketing autrhorisation (TMA). It is only prescribed and delivered in hospital settings, Six official indications Its current indications are principally lepromatous nodular erythema, severe aphtosis, Jessner-Kanoff’s cutaneous lymphocyte infiltration, discoid lupus erythematosis, chronic graft-versus-host reactions, and relapsed and or refractory multiple myeloma (after the failure of standard therapies). In the majority of cases, thalidomide is a last resort treatment of rare pathologies. On withdrawal, it is responsible for more or less long-term reccurrences of the disease that require its re-introduction. Surveillance is crucial. The side effects induced by thalidomide must never be forgotten, notably its teratogenic effects and its often irreversible neurotoxicity. The latter limit the long-term use of thalidomide and imply strict rules for its prescription and surveillance (efficient contraception, clinical neurological examinations, electroneurophysiological controls).
Keywords:
Abnormalities, Drug-Induced/prevention & control*
Adult
Female
France
Humans
Immunosuppressive Agents/adverse effects*
Immunosuppressive Agents/therapeutic use*
Male
Monitoring, Physiologic
Nervous System Diseases/chemically induced
Thalidomide/adverse effects*
Thalidomide/therapeutic use*
